Literature DB >> 16086186

Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease.

E K Tan1, H Shen, J M M Tan, K L Lim, S Fook-Chong, W P Hu, M C Paterson, V R Chandran, K Yew, C Tan, Y Yuen, R Pavanni, M C Wong, K Puvan, Y Zhao.   

Abstract

BACKGROUND: Altered splicing of parkin under cellular stress could lead to changes in gene expression and altered protein activity. The causative role of parkin in sporadic Parkinson's disease (PD) is unknown.
OBJECTIVES: We described a parkin splice variant (SV) in the substantia nigra and leukocytes of sporadic PD patients. Using a case control methodology, we investigated the exon 4 SV (E4SV) and wild-type parkin expression in the leukocytes of sporadic PD patients and healthy individuals. METHODS/
RESULTS: We identified a parkin E4SV in the substantia nigra and leukocytes of sporadic PD patients and controls by reverse transcriptase-polymerase chain reaction (PCR). The exon 4 (122 bp) deletion resulted in a reading frame shift over the junction of exons 3-5 and a stop codon (tga) 17 bp downstream from exon 3. The translated truncated protein was associated with a total loss of the two-RING finger functional domain. Utilizing TaqMan real-time PCR with probes located across the junction of exons 3-4 or 3-5, we demonstrated an over-expression of E4SV/wild-type parkin ratio in the leukocytes of sporadic PD patients compared to age-, gender-, and race-matched controls (p<0.0005). A multivariate regression analysis demonstrated that the ratio of E4SV/wild-type parkin expression increased with age in PD patients, but this was not observed in the controls (p<0.0005).
CONCLUSION: The relative expression of E4SV/wild type parkin was increased in sporadic PD compared to healthy controls. Based on our observations, further functional studies to determine the pathophysiologic role of E4SV in sporadic PD patients will be of importance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086186     DOI: 10.1007/s10048-005-0001-5

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  Caspase-mediated parkin cleavage in apoptotic cell death.

Authors:  Soren Kahns; Simon Lykkebo; Lene Diness Jakobsen; Morten S Nielsen; Poul Henning Jensen
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Differential expression of the parkin gene in the human brain and peripheral leukocytes.

Authors:  Y Sunada; F Saito; K Matsumura; T Shimizu
Journal:  Neurosci Lett       Date:  1998-10-02       Impact factor: 3.046

5.  Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene.

Authors:  T Kitada; S Asakawa; S Minoshima; Y Mizuno; N Shimizu
Journal:  Mamm Genome       Date:  2000-06       Impact factor: 2.957

Review 6.  The genetics of Parkinson's disease.

Authors:  Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.

Authors:  Aaron C Pawlyk; Benoit I Giasson; Deepak M Sampathu; Francisco A Perez; Kah Leong Lim; Valina L Dawson; Ted M Dawson; Richard D Palmiter; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2003-09-12       Impact factor: 5.157

8.  Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation.

Authors:  Louis C Tan; Caroline M Tanner; Rong Chen; Piu Chan; Matthew Farrer; John Hardy; J William Langston
Journal:  Mov Disord       Date:  2003-07       Impact factor: 10.338

9.  Complex relationship between Parkin mutations and Parkinson disease.

Authors:  Andrew West; Magali Periquet; Sarah Lincoln; Christoph B Lücking; David Nicholl; Vincenzo Bonifati; Nina Rawal; Thomas Gasser; Ebba Lohmann; Jean-François Deleuze; Demetrius Maraganore; Allan Levey; Nick Wood; Alexandra Dürr; John Hardy; Alexis Brice; Matt Farrer
Journal:  Am J Med Genet       Date:  2002-07-08

10.  Altered expression of the glutamate transporter EAAT2b in neurological disease.

Authors:  Nicholas J Maragakis; Margaret Dykes-Hoberg; Jeffrey D Rothstein
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

View more
  10 in total

1.  DEGAS: de novo discovery of dysregulated pathways in human diseases.

Authors:  Igor Ulitsky; Akshay Krishnamurthy; Richard M Karp; Ron Shamir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

2.  Proteomic Analysis of Parkin Isoforms Expression in Different Rat Brain Areas.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Rita Reitano; Sebastiano Cavallaro; Velia D'Agata
Journal:  Protein J       Date:  2016-10       Impact factor: 2.371

3.  Expression pattern of parkin isoforms in lung adenocarcinomas.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Gaetano Magro; Lucia Salvatorelli; Filippo Drago; Velia D'Agata
Journal:  Tumour Biol       Date:  2015-02-06

4.  SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Authors:  Lina A Shehadeh; Kristine Yu; Liyong Wang; Alexandra Guevara; Carlos Singer; Jeffery Vance; Spyridon Papapetropoulos
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

5.  Neuronal gene expression correlates of Parkinson's disease with dementia.

Authors:  Chelsea Stamper; Andrew Siegel; Winnie S Liang; John V Pearson; Dietrich A Stephan; Holly Shill; Don Connor; John N Caviness; Marwan Sabbagh; Thomas G Beach; Charles H Adler; Travis Dunckley
Journal:  Mov Disord       Date:  2008-08-15       Impact factor: 10.338

6.  Cloning of a conserved receptor-like protein kinase gene and its use as a functional marker for homoeologous group-2 chromosomes of the triticeae species.

Authors:  Bi Qin; Tingting Chen; Aizhong Cao; Haiyan Wang; Liping Xing; Hongqing Ling; Daowen Wang; Chunmei Yu; Jin Xiao; Jianhui Ji; Xueluan Chen; Peidu Chen; Dajun Liu; Xiue Wang
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

Review 7.  Splicing: is there an alternative contribution to Parkinson's disease?

Authors:  Valentina La Cognata; Velia D'Agata; Francesca Cavalcanti; Sebastiano Cavallaro
Journal:  Neurogenetics       Date:  2015-05-16       Impact factor: 2.660

8.  Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene.

Authors:  Valentina La Cognata; Rosario Iemmolo; Velia D'Agata; Soraya Scuderi; Filippo Drago; Mario Zappia; Sebastiano Cavallaro
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

9.  Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.

Authors:  Soraya Scuderi; Valentina La Cognata; Filippo Drago; Sebastiano Cavallaro; Velia D'Agata
Journal:  Biomed Res Int       Date:  2014-07-16       Impact factor: 3.411

10.  Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.

Authors:  Judith A Potashkin; Jose A Santiago; Bernard M Ravina; Arthur Watts; Alexey A Leontovich
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.